A randomized, open-label, two arm trial to compare the safety and antiviral efficacy of GW433908 [fosamprenavir]/ritonavir QD [daily] to nelfinavir BID [twice daily] when used in combination with abacavir and lamivudine for 48 weeks in antiretroviral therapy naive HIV-1 infected subjects.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2005
At a glance
- Drugs Fosamprenavir; Lamivudine/abacavir; Nelfinavir; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- 20 Oct 2005 New trial record.